{"id":175405,"date":"2022-07-05T00:00:00","date_gmt":"2022-07-04T22:00:00","guid":{"rendered":"https:\/\/www.bcfi.be\/impact-de-la-supplementation-en-vitamine-d-sur-la-mortalite\/"},"modified":"2026-04-02T19:09:21","modified_gmt":"2026-04-02T17:09:21","slug":"impact-de-la-supplementation-en-vitamine-d-sur-la-mortalite","status":"publish","type":"post","link":"https:\/\/beta.cbip.be\/fr\/impact-de-la-supplementation-en-vitamine-d-sur-la-mortalite\/","title":{"rendered":"Impact de la suppl\u00e9mentation en vitamine D sur la mortalit\u00e9"},"content":{"rendered":"<h2>Message cl&eacute;<\/h2>\n<ul>\n<li>\n<p>L&rsquo;&eacute;tude D-Health est une RCT &agrave; grande &eacute;chelle qui montre que la prise pr&eacute;ventive de compl&eacute;ments de vitamine&nbsp;D &agrave; fortes doses mensuelles dans une population de personnes &acirc;g&eacute;es de plus de 60&nbsp;ans n&rsquo;a pas d&rsquo;effet sur la mortalit&eacute; totale.<\/p>\n<\/li>\n<\/ul>\n<h2>En quoi cette &eacute;tude est-elle importante ?<\/h2>\n<ul>\n<li>\n<p>Dans les sciences fondamentales&#x002C; la vitamine D a &eacute;t&eacute; associ&eacute;e &agrave; de nombreux effets (protecteurs). Dans plusieurs &eacute;tudes observationnelles&#x002C; des niveaux plus &eacute;lev&eacute;s de vitamine&nbsp;D ont &eacute;t&eacute; associ&eacute;s &agrave; des effets protecteurs sur le risque cardiovasculaire&#x002C; le risque de cancer et la survie globale. Ce type d&rsquo;&eacute;tudes est plus susceptible de comporter des biais et ne permet pas de prouver le b&eacute;n&eacute;fice d&rsquo;une suppl&eacute;mentation en vitamine D<!--[if supportFields]><span style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-ansi-language:NL-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'><span style='mso-element:field-begin'><\/span> ADDIN ZOTERO_ITEM CSL_CITATION {&quot;citationID&quot;:&quot;QwMt2XCS&quot;&#x002C;&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\super 1&#x002C;2\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\osupersub{}&quot;&#x002C;&quot;plainCitation&quot;:&quot;1&#x002C;2&quot;&#x002C;&quot;noteIndex&quot;:0}&#x002C;&quot;citationItems&quot;:[{&quot;id&quot;:142&#x002C;&quot;uris&quot;:[&quot;https:\/\/zotero.org\/users\/local\/DTrOoUEd\/items\/QFGAX6KG&quot;]&#x002C;&quot;itemData&quot;:{&quot;id&quot;:142&#x002C;&quot;type&quot;:&quot;article-journal&quot;&#x002C;&quot;abstract&quot;:&quot;Epidemiological studies indicate that vitamin D insufficiency could have an aetiological role in various human cancers. Preclinical research indicates that the active metabolite of vitamin D&#x002C; 1alpha&#x002C;25(OH)2D3&#x002C; also known as calcitriol&#x002C; or vitamin D analogues might have potential as anticancer agents \u2026&quot;&#x002C;&quot;container-title&quot;:&quot;Nature reviews. Cancer&quot;&#x002C;&quot;DOI&quot;:&quot;10.1038\/nrc2196&quot;&#x002C;&quot;ISSN&quot;:&quot;1474-175X&quot;&#x002C;&quot;issue&quot;:&quot;9&quot;&#x002C;&quot;language&quot;:&quot;en&quot;&#x002C;&quot;note&quot;:&quot;publisher: Nat Rev Cancer\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\PMID: 17721433&quot;&#x002C;&quot;source&quot;:&quot;pubmed.ncbi.nlm.nih.gov&quot;&#x002C;&quot;title&quot;:&quot;Vitamin D signalling pathways in cancer: potential for anticancer therapeutics&quot;&#x002C;&quot;title-short&quot;:&quot;Vitamin D signalling pathways in cancer&quot;&#x002C;&quot;URL&quot;:&quot;https:\/\/pubmed.ncbi.nlm.nih.gov\/17721433\/&quot;&#x002C;&quot;volume&quot;:&quot;7&quot;&#x002C;&quot;author&quot;:[{&quot;family&quot;:&quot;Kristin K&quot;&#x002C;&quot;given&quot;:&quot;Deeb&quot;}&#x002C;{&quot;family&quot;:&quot;Donald L.&quot;&#x002C;&quot;given&quot;:&quot;Trump&quot;}&#x002C;{&quot;family&quot;:&quot;Candace S&quot;&#x002C;&quot;given&quot;:&quot;Johnson&quot;}]&#x002C;&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2022&quot;&#x002C;1&#x002C;27]]}&#x002C;&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2007&quot;&#x002C;9]]}}}&#x002C;{&quot;id&quot;:117&#x002C;&quot;uris&quot;:[&quot;https:\/\/zotero.org\/users\/local\/DTrOoUEd\/items\/TILBFEC3&quot;]&#x002C;&quot;itemData&quot;:{&quot;id&quot;:117&#x002C;&quot;type&quot;:&quot;article-journal&quot;&#x002C;&quot;abstract&quot;:&quot;Background The effect of supplementing unscreened adults with vitamin D3 on mortality is unclear. We aimed to determine whether monthly doses of vitamin D3 influenced mortality in older Australians.&quot;&#x002C;&quot;container-title&quot;:&quot;The Lancet Diabetes &amp; Endocrinology&quot;&#x002C;&quot;DOI&quot;:&quot;10.1016\/S2213-8587(21)00345-4&quot;&#x002C;&quot;ISSN&quot;:&quot;22138587&quot;&#x002C;&quot;issue&quot;:&quot;2&quot;&#x002C;&quot;journalAbbreviation&quot;:&quot;The Lancet Diabetes &amp; Endocrinology&quot;&#x002C;&quot;language&quot;:&quot;en&quot;&#x002C;&quot;page&quot;:&quot;120-128&quot;&#x002C;&quot;source&quot;:&quot;DOI.org (Crossref)&quot;&#x002C;&quot;title&quot;:&quot;The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality&quot;&#x002C;&quot;title-short&quot;:&quot;The D-Health Trial&quot;&#x002C;&quot;volume&quot;:&quot;10&quot;&#x002C;&quot;author&quot;:[{&quot;family&quot;:&quot;Neale&quot;&#x002C;&quot;given&quot;:&quot;Rachel E&quot;}&#x002C;{&quot;family&quot;:&quot;Baxter&quot;&#x002C;&quot;given&quot;:&quot;Catherine&quot;}&#x002C;{&quot;family&quot;:&quot;Romero&quot;&#x002C;&quot;given&quot;:&quot;Briony Duarte&quot;}&#x002C;{&quot;family&quot;:&quot;McLeod&quot;&#x002C;&quot;given&quot;:&quot;Donald S A&quot;}&#x002C;{&quot;family&quot;:&quot;English&quot;&#x002C;&quot;given&quot;:&quot;Dallas R&quot;}&#x002C;{&quot;family&quot;:&quot;Armstrong&quot;&#x002C;&quot;given&quot;:&quot;Bruce K&quot;}&#x002C;{&quot;family&quot;:&quot;Ebeling&quot;&#x002C;&quot;given&quot;:&quot;Peter R&quot;}&#x002C;{&quot;family&quot;:&quot;Hartel&quot;&#x002C;&quot;given&quot;:&quot;Gunter&quot;}&#x002C;{&quot;family&quot;:&quot;Kimlin&quot;&#x002C;&quot;given&quot;:&quot;Michael G&quot;}&#x002C;{&quot;family&quot;:&quot;O'Connell&quot;&#x002C;&quot;given&quot;:&quot;Rachel&quot;}&#x002C;{&quot;family&quot;:&quot;Pols&quot;&#x002C;&quot;given&quot;:&quot;Jolieke C&quot;&#x002C;&quot;non-dropping-particle&quot;:&quot;van der&quot;}&#x002C;{&quot;family&quot;:&quot;Venn&quot;&#x002C;&quot;given&quot;:&quot;Alison J&quot;}&#x002C;{&quot;family&quot;:&quot;Webb&quot;&#x002C;&quot;given&quot;:&quot;Penelope M&quot;}&#x002C;{&quot;family&quot;:&quot;Whiteman&quot;&#x002C;&quot;given&quot;:&quot;David C&quot;}&#x002C;{&quot;family&quot;:&quot;Waterhouse&quot;&#x002C;&quot;given&quot;:&quot;Mary&quot;}]&#x002C;&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2022&quot;&#x002C;2]]}}}]&#x002C;&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;} <span style='mso-element:field-separator'><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>1&#x002C;2<\/sup><\/span><!--[if supportFields]><span style='font-size:12.0pt; font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-hansi-theme-font:minor-latin;mso-ansi-language:NL-BE;mso-fareast-language: NL-BE;mso-bidi-language:AR-SA'><span style='mso-element:field-end'><\/span><\/span><![endif]-->.<\/p>\n<\/li>\n<li>\n<p>Avant l&rsquo;&eacute;tude D-Health&#x002C; il y a eu l&rsquo;&eacute;tude VITAL<!--[if supportFields]><span lang=FR style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'><span style='mso-element:field-begin'><\/span><\/span><span lang=FR-BE style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-ansi-language:FR-BE;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'> ADDIN ZOTERO_ITEM CSL_CITATION {&quot;citationID&quot;:&quot;p9s7nIgF&quot;&#x002C;&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\super 3\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\osupersub{}&quot;&#x002C;&quot;plainCitation&quot;:&quot;3&quot;&#x002C;&quot;noteIndex&quot;:0}&#x002C;&quot;citationItems&quot;:[{&quot;id&quot;:418&#x002C;&quot;uris&quot;:[&quot;https:\/\/zotero.org\/users\/local\/DTrOoUEd\/items\/PXWRVSTH&quot;]&#x002C;&quot;itemData&quot;:{&quot;id&quot;:418&#x002C;&quot;type&quot;:&quot;article-journal&quot;&#x002C;&quot;abstract&quot;:&quot;Vitamin D and Cancer and Cardiovascular Disease This article reports the vitamin D portion of a randomized&#x002C; two-by-two factorial trial of n\u22123 fatty acids and vitamin D in the prevention of cancer and cardiovascular disease. Vitamin D did not result in a lower incidence of invasive cancer or cardiovascular events than placebo.&quot;&#x002C;&quot;container-title&quot;:&quot;New England Journal of Medicine&quot;&#x002C;&quot;DOI&quot;:&quot;10.1056\/NEJMoa1809944&quot;&#x002C;&quot;ISSN&quot;:&quot;0028-4793&quot;&#x002C;&quot;issue&quot;:&quot;1&quot;&#x002C;&quot;note&quot;:&quot;publisher: Massachusetts Medical Society\\\\\\\\\\\\\\_eprint: https:\/\/doi.org\/10.1056\/NEJMoa1809944\\\\\\\\\\\\\\PMID: 30415629&quot;&#x002C;&quot;page&quot;:&quot;33-44&quot;&#x002C;&quot;source&quot;:&quot;Taylor and Francis+NEJM&quot;&#x002C;&quot;title&quot;:&quot;Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease&quot;&#x002C;&quot;volume&quot;:&quot;380&quot;&#x002C;&quot;author&quot;:[{&quot;family&quot;:&quot;Manson&quot;&#x002C;&quot;given&quot;:&quot;JoAnn E.&quot;}&#x002C;{&quot;family&quot;:&quot;Cook&quot;&#x002C;&quot;given&quot;:&quot;Nancy R.&quot;}&#x002C;{&quot;family&quot;:&quot;Lee&quot;&#x002C;&quot;given&quot;:&quot;I-Min&quot;}&#x002C;{&quot;family&quot;:&quot;Christen&quot;&#x002C;&quot;given&quot;:&quot;William&quot;}&#x002C;{&quot;family&quot;:&quot;Bassuk&quot;&#x002C;&quot;given&quot;:&quot;Shari S.&quot;}&#x002C;{&quot;family&quot;:&quot;Mora&quot;&#x002C;&quot;given&quot;:&quot;Samia&quot;}&#x002C;{&quot;family&quot;:&quot;Gibson&quot;&#x002C;&quot;given&quot;:&quot;Heike&quot;}&#x002C;{&quot;family&quot;:&quot;Gordon&quot;&#x002C;&quot;given&quot;:&quot;David&quot;}&#x002C;{&quot;family&quot;:&quot;Copeland&quot;&#x002C;&quot;given&quot;:&quot;Trisha&quot;}&#x002C;{&quot;family&quot;:&quot;D\u2019Agostino&quot;&#x002C;&quot;given&quot;:&quot;Denise&quot;}&#x002C;{&quot;family&quot;:&quot;Friedenberg&quot;&#x002C;&quot;given&quot;:&quot;Georgina&quot;}&#x002C;{&quot;family&quot;:&quot;Ridge&quot;<\/span><span lang=FR style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'>&#x002C;&quot;given&quot;:&quot;Claire&quot;}&#x002C;{&quot;family&quot;:&quot;Bubes&quot;&#x002C;&quot;given&quot;:&quot;Vadim&quot;}&#x002C;{&quot;family&quot;:&quot;Giovannucci&quot;&#x002C;&quot;given&quot;:&quot;Edward L.&quot;}&#x002C;{&quot;family&quot;:&quot;Willett&quot;&#x002C;&quot;given&quot;:&quot;Walter C.&quot;}&#x002C;{&quot;family&quot;:&quot;Buring&quot;&#x002C;&quot;given&quot;:&quot;Julie E.&quot;}]&#x002C;&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2019&quot;&#x002C;1&#x002C;3]]}}}]&#x002C;&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;} <span style='mso-element:field-separator'><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>3<\/sup><\/span><!--[if supportFields]><span lang=FR style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-ascii-theme-font: minor-latin;mso-fareast-font-family:Calibri;mso-hansi-theme-font:minor-latin; mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'><span style='mso-element:field-end'><\/span><\/span><![endif]-->&#x002C; une RCT &agrave; grande &eacute;chelle de 2020 qui n&rsquo;a pas pu d&eacute;montrer d&rsquo;effet avec une forte dose quotidienne de vitamine D (2 000 UI par jour) sur l&rsquo;incidence des maladies cardiovasculaires et des cancers invasifs&#x002C; pas plus que&nbsp;sur la mortalit&eacute; globale (cf. plus d&rsquo;infos).<\/p>\n<\/li>\n<li>\n<p>Il y a &eacute;galement une m&eacute;ta-analyse de RCT qui a &eacute;valu&eacute; les effets d&rsquo;une suppl&eacute;mentation en vitamine&nbsp;D sur la mortalit&eacute;. Dans cette m&eacute;ta-analyse&#x002C; la prise de compl&eacute;ments de vitamine&nbsp;D n&rsquo;a pas &eacute;t&eacute; associ&eacute;e &agrave; un effet sur la mortalit&eacute; globale&#x002C; mais un effet a &eacute;t&eacute; constat&eacute; sur la mortalit&eacute; par cancer.<\/p>\n<div class='detailed-content'>\n<ul>\n<li>L&rsquo;&eacute;tude &laquo;&nbsp;VITamin D and OmegA-3&nbsp;&raquo; (VITAL) est une RCT qui a &eacute;valu&eacute; une dose quotidienne de vitamine&nbsp;D3 (2&nbsp;000&nbsp;UI) et d&rsquo;acides gras om&eacute;ga-3 (1&nbsp;g) sur le plan de la pr&eacute;vention primaire du cancer invasif et des affections cardiovasculaires pendant un suivi de 5&nbsp;ans. Sur les 25&nbsp;871&nbsp;participants&#x002C; 20&nbsp;pour cent environ &eacute;taient des Afro-Am&eacute;ricains. L&rsquo;&eacute;tude n&rsquo;a pas trouv&eacute; de r&eacute;duction de l&rsquo;incidence totale de cancer invasif (risque relatif&nbsp;: 0&#x002C;96&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;88 &#8211; 1&#x002C;06)&#x002C; de l&rsquo;incidence d&rsquo;&eacute;v&eacute;nements cardiovasculaires (risque relatif&nbsp;: 0&#x002C;97&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;85 &#8211; 1&#x002C;12) ou de la mortalit&eacute; globale (crit&egrave;re d&rsquo;&eacute;valuation secondaire&nbsp;; risque relatif&nbsp;: 0&#x002C;99&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;87 &#8211; 1&#x002C;12).<\/li>\n<li>La m&eacute;ta-analyse de Zhang et al.<!--[if supportFields]><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif; mso-fareast-font-family:Calibri;color:#0070C0;letter-spacing:-.1pt;mso-ansi-language: FR;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'><span style='mso-element: field-begin'><\/span> ADDIN ZOTERO_ITEM CSL_CITATION {&quot;citationID&quot;:&quot;YfJnaTi9&quot;&#x002C;&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\super 4\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\osupersub{}&quot;&#x002C;&quot;plainCitation&quot;:&quot;4&quot;&#x002C;&quot;noteIndex&quot;:0}&#x002C;&quot;citationItems&quot;:[{&quot;id&quot;:138&#x002C;&quot;uris&quot;:[&quot;https:\/\/zotero.org\/users\/local\/DTrOoUEd\/items\/L4ASZYAX&quot;]&#x002C;&quot;itemData&quot;:{&quot;id&quot;:138&#x002C;&quot;type&quot;:&quot;article-journal&quot;&#x002C;&quot;abstract&quot;:&quot;&lt;h3&gt;Abstract&lt;\/h3&gt; &lt;h3&gt;Objective&lt;\/h3&gt; &lt;p&gt;To investigate whether vitamin D supplementation is associated with lower mortality in adults.&lt;\/p&gt;&lt;h3&gt;Design&lt;\/h3&gt; &lt;p&gt;Systematic review and meta-analysis of randomised controlled trials.&lt;\/p&gt;&lt;h3&gt;Data sources&lt;\/h3&gt; &lt;p&gt;Medline&#x002C; Embase&#x002C; and the Cochrane Central Register from their inception to 26 December 2018.&lt;\/p&gt;&lt;h3&gt;Eligibility criteria for selecting studies&lt;\/h3&gt; &lt;p&gt;Randomised controlled trials comparing vitamin D supplementation with a placebo or no treatment for mortality were included. Independent data extraction was conducted and study quality assessed. A meta-analysis was carried out by using fixed effects and random effects models to calculate risk ratio of death in the group receiving vitamin D supplementation and the control group.&lt;\/p&gt;&lt;h3&gt;Main outcome measures&lt;\/h3&gt; &lt;p&gt;All cause mortality.&lt;\/p&gt;&lt;h3&gt;Results&lt;\/h3&gt; &lt;p&gt;50 trials with a total of 74 655 participants were identified. Vitamin D supplementation was not associated with all cause mortality (risk ratio 0.98&#x002C; 95% confidence interval 0.95 to 1.02&#x002C; I&lt;sup&gt;2&lt;\/sup&gt;=0%)&#x002C; cardiovascular mortality (0.98&#x002C; 0.88 to 1.08&#x002C; 0%)&#x002C; or non-cancer&#x002C; non-cardiovascular mortality (1.05&#x002C; 0.93 to 1.18&#x002C; 0%). Vitamin D supplementation statistically significantly reduced the risk of cancer death (0.85&#x002C; 0.74 to 0.97&#x002C; 0%). In subgroup analyses&#x002C; all cause mortality was significantly lower in trials with vitamin D&lt;sub&gt;3&lt;\/sub&gt; supplementation than in trials with vitamin D&lt;sub&gt;2&lt;\/sub&gt; supplementation (P for interaction=0.04); neither vitamin D&lt;sub&gt;3&lt;\/sub&gt; nor vitamin D&lt;sub&gt;2&lt;\/sub&gt; was associated with a statistically significant reduction in all cause mortality.&lt;\/p&gt;&lt;h3&gt;Conclusions&lt;\/h3&gt; &lt;p&gt;Vitamin D supplementation alone was not associated with all cause mortality in adults compared with placebo or no treatment. Vitamin D supplementation reduced the risk of cancer death by 15%. Additional large clinical studies are needed to determine whether vitamin D&lt;sub&gt;3&lt;\/sub&gt; supplementation is associated with lower all cause mortality.&lt;\/p&gt;&lt;h3&gt;Study registration&lt;\/h3&gt; &lt;p&gt;PROSPERO registration number CRD42018117823.&lt;\/p&gt;&quot;&#x002C;&quot;container-title&quot;:&quot;BMJ&quot;&#x002C;&quot;DOI&quot;:&quot;10.1136\/bmj.l4673&quot;&#x002C;&quot;ISSN&quot;:&quot;1756-1833&quot;&#x002C;&quot;journalAbbreviation&quot;:&quot;BMJ&quot;&#x002C;&quot;language&quot;:&quot;en&quot;&#x002C;&quot;note&quot;:&quot;publisher: British Medical Journal Publishing Group\\\\\\\\\\\\\\section: Research\\\\\\\\\\\\\\PMID: 31405892&quot;&#x002C;&quot;source&quot;:&quot;www.bmj.com&quot;&#x002C;&quot;title&quot;:&quot;Association between vitamin D supplementation and mortality: systematic review and meta-analysis&quot;&#x002C;&quot;title-short&quot;:&quot;Association between vitamin D supplementation and mortality&quot;&#x002C;&quot;URL&quot;:&quot;https:\/\/www.bmj.com\/content\/366\/bmj.l4673&quot;&#x002C;&quot;volume&quot;:&quot;366&quot;&#x002C;&quot;author&quot;:[{&quot;family&quot;:&quot;Zhang&quot;&#x002C;&quot;given&quot;:&quot;Yu&quot;}&#x002C;{&quot;family&quot;:&quot;Fang&quot;&#x002C;&quot;given&quot;:&quot;Fang&quot;}&#x002C;{&quot;family&quot;:&quot;Tang&quot;&#x002C;&quot;given&quot;:&quot;Jingjing&quot;}&#x002C;{&quot;family&quot;:&quot;Jia&quot;&#x002C;&quot;given&quot;:&quot;Lu&quot;}&#x002C;{&quot;family&quot;:&quot;Feng&quot;&#x002C;&quot;given&quot;:&quot;Yuning&quot;}&#x002C;{&quot;family&quot;:&quot;Xu&quot;&#x002C;&quot;given&quot;:&quot;Ping&quot;}&#x002C;{&quot;family&quot;:&quot;Faramand&quot;&#x002C;&quot;given&quot;:&quot;Andrew&quot;}]&#x002C;&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2022&quot;&#x002C;1&#x002C;27]]}&#x002C;&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2019&quot;&#x002C;8&#x002C;12]]}}}]&#x002C;&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;} <span style='mso-element:field-separator'><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>4<\/sup><\/span><!--[if supportFields]><span lang=FR style='font-size:11.0pt;mso-bidi-font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif; mso-fareast-font-family:Calibri;color:#0070C0;letter-spacing:-.1pt;mso-ansi-language: FR;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'><span style='mso-element: field-end'><\/span><\/span><![endif]-->&#x002C; qui a inclus 50&nbsp;RCT totalisant 74&nbsp;655&nbsp;participants et assurant un suivi m&eacute;dian d&rsquo;un an&#x002C; n&rsquo;a pas mis au jour de r&eacute;duction de la mortalit&eacute; toutes causes confondues (risque relatif&nbsp;: 0&#x002C;98&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;95 &#8211; 1&#x002C;02)&#x002C; de la mortalit&eacute; cardiovasculaire (risque relatif&nbsp;: 0&#x002C;98&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;88 &#8211; 1&#x002C;08) ou de la mortalit&eacute; due &agrave; d&rsquo;autres causes qu&rsquo;un cancer ou une maladie cardiovasculaire (risque relatif&nbsp;: 1&#x002C;05&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;93 &#8211; 1&#x002C;18) en cas de prophylaxie &agrave; base de compl&eacute;ments de vitamine&nbsp;D. Les auteurs ont cependant observ&eacute; un effet sur la mortalit&eacute; par cancer (risque relatif&nbsp;: 0&#x002C;85&nbsp;; IC 95&nbsp;%&nbsp;: 0&#x002C;74 &#8211; 0&#x002C;97).<\/li>\n<li>Il convient toutefois d&rsquo;ajouter quelques notes critiques dans la discussion de ces m&eacute;ta-analyses&#x002C; en ce sens o&ugrave; les &eacute;tudes &eacute;taient souvent de courte dur&eacute;e et portaient sur des populations r&eacute;duites&#x002C; sur diff&eacute;rentes cat&eacute;gories d&#39;&acirc;ge&#x002C; diff&eacute;rents groupes ethniques et diff&eacute;rents sch&eacute;mas posologiques. De ce fait&#x002C; il est impossible d&rsquo;&eacute;tablir un lien causal entre des doses d&eacute;termin&eacute;es et des r&eacute;sultats cliniques.<\/li>\n<\/ul><\/div>\n<\/li>\n<li>\n<p>Aucune RCT men&eacute;e &agrave; grande &eacute;chelle et\/ou &agrave; long terme n&rsquo;a pu confirmer l&#39;effet positif sur la mortalit&eacute; constat&eacute; dans les &eacute;tudes observationnelles.<\/p>\n<\/li>\n<\/ul>\n<h2> Conception de l&rsquo;&eacute;tude<\/h2>\n<ul>\n<li>\n<p>D-Health est une &eacute;tude &agrave; grande &eacute;chelle&#x002C; randomis&eacute;e&#x002C; en double aveugle&#x002C; contr&ocirc;l&eacute;e contre placebo et d&rsquo;une dur&eacute;e de 5&nbsp;ans&#x002C; dans laquelle le groupe actif a re&ccedil;u mensuellement 60&nbsp;000&nbsp;UI de vitamine&nbsp;D3&#x002C; ce qui correspond &agrave; un apport quotidien de 2&nbsp;000&nbsp;UI. Les crit&egrave;res d&rsquo;inclusion &eacute;taient un &acirc;ge compris entre 60 et 84&nbsp;ans&#x002C; l&rsquo;absence de prise quotidienne de plus de 500&nbsp;UI de compl&eacute;ments de vitamine&nbsp;D et l&rsquo;absence d&rsquo;ant&eacute;c&eacute;dents autod&eacute;clar&eacute;s de calculs r&eacute;naux&#x002C; d&rsquo;hypercalc&eacute;mie&#x002C; d&rsquo;hyperparathyro&iuml;die&#x002C; d&rsquo;ost&eacute;omalacie ou de sarco&iuml;dose.<\/p>\n<\/li>\n<li>\n<p>Tous les participants du groupe actif ont re&ccedil;u douze g&eacute;lules de 60&nbsp;000&nbsp;UI de vitamine&nbsp;D par an. Leur observance th&eacute;rapeutique a &eacute;t&eacute; &eacute;valu&eacute;e au moyen de questionnaires.<\/p>\n<\/li>\n<li>\n<p>Le crit&egrave;re d&rsquo;&eacute;valuation primaire &eacute;tait la mortalit&eacute; globale. Les crit&egrave;res d&rsquo;&eacute;valuation secondaires &eacute;taient l&rsquo;incidence totale de cancer&#x002C; l&rsquo;incidence de cancer colorectal&#x002C;&nbsp;la mortalit&eacute; cardiovasculaire et la mortalit&eacute; par cancer.<\/p>\n<\/li>\n<\/ul>\n<h2> R&eacute;sultats en bref<\/h2>\n<ul>\n<li>\n<p>Au total&#x002C; l&rsquo;&eacute;tude a inclus 21&nbsp;310&nbsp;participants dans les deux groupes. 54&#x002C;1&nbsp;% de ces participants &eacute;taient de sexe masculin et l&rsquo;&acirc;ge moyen &eacute;tait de 69&#x002C;3&nbsp;ans.<\/p>\n<\/li>\n<li>\n<p>La concentration s&eacute;rique de vitamine&nbsp;D n&rsquo;a pas &eacute;t&eacute; mesur&eacute;e au d&eacute;but de l&rsquo;&eacute;tude. La concentration s&eacute;rique moyenne de 25(OH)vitamine&nbsp;D a &eacute;t&eacute; mesur&eacute;e tous les ans pendant les 5&nbsp;ann&eacute;es de l&rsquo;&eacute;tude. Elle s&rsquo;&eacute;levait en moyenne &agrave; 77&nbsp;nmol\/l dans le groupe placebo et &agrave; 115&nbsp;nmol\/l dans le groupe vitamine&nbsp;D.<\/p>\n<\/li>\n<li>\n<p>L&rsquo;observance th&eacute;rapeutique s&rsquo;est r&eacute;v&eacute;l&eacute;e &eacute;lev&eacute;e&nbsp;: 84&#x002C;5&nbsp;pour cent des participants du groupe actif et 82&#x002C;5&nbsp;pour cent des participants du groupe placebo ont pris au moins 80&nbsp;% des g&eacute;lules pendant toute la p&eacute;riode de traitement.<\/p>\n<\/li>\n<li>\n<p>Apr&egrave;s un suivi m&eacute;dian de 5&#x002C;7 ans&#x002C; 1 100 d&eacute;c&egrave;s ont &eacute;t&eacute; enregistr&eacute;s&#x002C; dont 5&#x002C;1 % dans le groupe placebo et 5&#x002C;3% dans le groupe vitamine D.<\/p>\n<\/li>\n<li>\n<p>On n&rsquo;a pas observ&eacute; de diff&eacute;rence significative en termes de mortalit&eacute; globale&#x002C; de mortalit&eacute; cardiovasculaire ou de mortalit&eacute; par cancer (pour le traitement par vitamine D3 versus placebo&#x002C; respectivement&nbsp;: HR 1&#x002C;04 (IC &agrave; 95% de 0&#x002C;93 &agrave; 1&#x002C;18)&#x002C; 0&#x002C;96 (0&#x002C;72 &#8211; 1&#x002C;28) et 1&#x002C;15 (0&#x002C;96 &#8211; 1&#x002C;39)&#x002C; respectivement).<\/p>\n<\/li>\n<\/ul>\n<h2> <b>Commentaire du CBIP<\/b><\/h2>\n<ul>\n<li>\n<p>La dose&#x002C; de 60 000 UI par mois&#x002C; qui &eacute;tait utilis&eacute;e dans l&rsquo;&eacute;tude&#x002C; &eacute;tait une posologie &eacute;lev&eacute;e. Apr&egrave;s conversion en dose quotidienne&#x002C; cela revient &agrave; 2 000 UI par jour. Cette dose avait &eacute;t&eacute; choisie parce que&#x002C; dans la phase pilote&#x002C; elle avait permis d&#39;atteindre la concentration s&eacute;rique m&eacute;diane cible de<br \/> 75 nmol\/L de 25 OH vitamine D. Le r&eacute;pertoire recommande une dose quotidienne de 800 UI ou une dose mensuelle de 25 000 UI en pr&eacute;vention du d&eacute;ficit en vitamine D.<\/p>\n<\/li>\n<li>\n<p>Dans cette &eacute;tude&#x002C; les investigateurs ont utilis&eacute; une dose mensuelle de vitamine&nbsp;D. Une synth&egrave;se r&eacute;cente (li&eacute;e &agrave; l&rsquo;industrie pharmaceutique) a sugg&eacute;r&eacute; que le manque de donn&eacute;es probantes &eacute;tayant une influence positive des compl&eacute;ments de vitamine&nbsp;D sur les r&eacute;sultats cliniques pourrait &ecirc;tre d&ucirc; &agrave; l&rsquo;utilisation d&rsquo;un bolus plut&ocirc;t que d&rsquo;une dose quotidienne. Cette hypoth&egrave;se repose essentiellement sur deux r&eacute;centes m&eacute;ta-analyses&#x002C; qui ont not&eacute; une r&eacute;duction de l&rsquo;incidence d&rsquo;infections respiratoires lors de la prise d&rsquo;une dose quotidienne de vitamine&nbsp;D&#x002C; mais pas lors de la prise d&rsquo;un bolus<!--[if supportFields]><span lang=FR style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-fareast-font-family: Calibri;color:black;mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language: AR-SA'><span style='mso-element:field-begin'><\/span> ADDIN ZOTERO_ITEM CSL_CITATION {&quot;citationID&quot;:&quot;y66uLeHr&quot;&#x002C;&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\super 6\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\osupersub{}&quot;&#x002C;&quot;plainCitation&quot;:&quot;6&quot;&#x002C;&quot;noteIndex&quot;:0}&#x002C;&quot;citationItems&quot;:[{&quot;id&quot;:265&#x002C;&quot;uris&quot;:[&quot;https:\/\/zotero.org\/users\/local\/DTrOoUEd\/items\/MC4UZICB&quot;]&#x002C;&quot;itemData&quot;:{&quot;id&quot;:265&#x002C;&quot;type&quot;:&quot;article-journal&quot;&#x002C;&quot;abstract&quot;:&quot;In this review we summarize the impact of bolus versus daily dosing of vitamin D on 25(OH)D and 1&#x002C;25(OH)2D levels&#x002C; as well as on key countervailing factors that block vitamin D functions at the cellular level. Further&#x002C; we discuss the role of bolus versus daily dosing of vitamin D for several health outcomes&#x002C; including respiratory infections and coronavirus disease 2019 (COVID\u201019)&#x002C; rickets&#x002C; falls and fractures&#x002C; any cancer&#x002C; and cancer\u2010related mortality. This discussion appears timely because bolus doses continue to be tested for various disease outcomes despite a growing amount of evidence suggesting lack of efficacy or even detrimental effects of bolus dosing of vitamin D for outcomes where daily dosing at modest levels was effective in the vitamin D deficient. As a result&#x002C; these discordant results may bias health recommendations for vitamin D if the recommendations are based on meta\u2010analyses combining both daily and bolus dosing trials. \u00a9 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.&quot;&#x002C;&quot;container-title&quot;:&quot;JBMR Plus&quot;&#x002C;&quot;DOI&quot;:&quot;10.1002\/jbm4.10567&quot;&#x002C;&quot;ISSN&quot;:&quot;2473-4039&quot;&#x002C;&quot;issue&quot;:&quot;12&quot;&#x002C;&quot;journalAbbreviation&quot;:&quot;JBMR Plus&quot;&#x002C;&quot;note&quot;:&quot;PMID: 34950828\\\\\\\\\\\\\\PMCID: PMC8674779&quot;&#x002C;&quot;page&quot;:&quot;e10567&quot;&#x002C;&quot;source&quot;:&quot;PubMed Central&quot;&#x002C;&quot;title&quot;:&quot;Vitamin D: Bolus Is Bogus\u2014A Narrative Review&quot;&#x002C;&quot;title-short&quot;:&quot;Vitamin D&quot;&#x002C;&quot;volume&quot;:&quot;5&quot;&#x002C;&quot;author&quot;:[{&quot;family&quot;:&quot;Mazess&quot;&#x002C;&quot;given&quot;:&quot;Richard B.&quot;}&#x002C;{&quot;family&quot;:&quot;Bischoff\u2010Ferrari&quot;&#x002C;&quot;given&quot;:&quot;Heike A.&quot;}&#x002C;{&quot;family&quot;:&quot;Dawson\u2010Hughes&quot;&#x002C;&quot;given&quot;:&quot;Bess&quot;}]&#x002C;&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2021&quot;&#x002C;10&#x002C;30]]}}}]&#x002C;&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;} <span style='mso-element:field-separator'><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>6<\/sup><\/span><!--[if supportFields]><span lang=FR style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-fareast-font-family: Calibri;color:black;mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language: AR-SA'><span style='mso-element:field-end'><\/span><\/span><![endif]-->. En outre&#x002C; la m&eacute;ta-analyse de Keum et al.<!--[if supportFields]><span lang=FR style='font-size:12.0pt; font-family:'Calibri'&#x002C;sans-serif;mso-fareast-font-family:Calibri;color:black; mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language:AR-SA'><span style='mso-element:field-begin'><\/span> ADDIN ZOTERO_ITEM CSL_CITATION {&quot;citationID&quot;:&quot;O9uMomAE&quot;&#x002C;&quot;properties&quot;:{&quot;formattedCitation&quot;:&quot;\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\super 5\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\osupersub{}&quot;&#x002C;&quot;plainCitation&quot;:&quot;5&quot;&#x002C;&quot;noteIndex&quot;:0}&#x002C;&quot;citationItems&quot;:[{&quot;id&quot;:145&#x002C;&quot;uris&quot;:[&quot;https:\/\/zotero.org\/users\/local\/DTrOoUEd\/items\/TZJSHR4S&quot;]&#x002C;&quot;itemData&quot;:{&quot;id&quot;:145&#x002C;&quot;type&quot;:&quot;article-journal&quot;&#x002C;&quot;abstract&quot;:&quot;In an updated meta-analysis of RCTs&#x002C; vitamin D supplementation significantly reduced total cancer mortality but did not reduce total cancer incidence.&quot;&#x002C;&quot;container-title&quot;:&quot;Annals of oncology : official journal of the European Society for Medical Oncology&quot;&#x002C;&quot;DOI&quot;:&quot;10.1093\/annonc\/mdz059&quot;&#x002C;&quot;ISSN&quot;:&quot;1569-8041&quot;&#x002C;&quot;issue&quot;:&quot;5&quot;&#x002C;&quot;language&quot;:&quot;en&quot;&#x002C;&quot;note&quot;:&quot;publisher: Ann Oncol\\\\\\\\\\\\\\PMID: 30796437&quot;&#x002C;&quot;source&quot;:&quot;pubmed.ncbi.nlm.nih.gov&quot;&#x002C;&quot;title&quot;:&quot;Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials&quot;&#x002C;&quot;title-short&quot;:&quot;Vitamin D supplementation and total cancer incidence and mortality&quot;&#x002C;&quot;URL&quot;:&quot;https:\/\/pubmed.ncbi.nlm.nih.gov\/30796437\/&quot;&#x002C;&quot;volume&quot;:&quot;30&quot;&#x002C;&quot;author&quot;:[{&quot;family&quot;:&quot;Keum&quot;&#x002C;&quot;given&quot;:&quot;N&quot;}&#x002C;{&quot;family&quot;:&quot;Lee&quot;&#x002C;&quot;given&quot;:&quot;D.H&quot;}&#x002C;{&quot;family&quot;:&quot;Greenwood&quot;&#x002C;&quot;given&quot;:&quot;D.C&quot;}&#x002C;{&quot;family&quot;:&quot;Manson&quot;&#x002C;&quot;given&quot;:&quot;J.E&quot;}&#x002C;{&quot;family&quot;:&quot;Giovannucci&quot;&#x002C;&quot;given&quot;:&quot;E&quot;}]&#x002C;&quot;accessed&quot;:{&quot;date-parts&quot;:[[&quot;2022&quot;&#x002C;1&#x002C;27]]}&#x002C;&quot;issued&quot;:{&quot;date-parts&quot;:[[&quot;2019&quot;&#x002C;5&#x002C;1]]}}}]&#x002C;&quot;schema&quot;:&quot;https:\/\/github.com\/citation-style-language\/schema\/raw\/master\/csl-citation.json&quot;} <span style='mso-element:field-separator'><\/span><\/span><![endif]--><span class='folia-referentie-nummer'><sup>5<\/sup><\/span><!--[if supportFields]><span lang=FR style='font-size:12.0pt;font-family:'Calibri'&#x002C;sans-serif;mso-fareast-font-family: Calibri;color:black;mso-ansi-language:FR;mso-fareast-language:NL-BE;mso-bidi-language: AR-SA'><span style='mso-element:field-end'><\/span><\/span><![endif]--> a &eacute;tabli que l&rsquo;administration de compl&eacute;ments de vitamine&nbsp;D avait un effet protecteur sur la mortalit&eacute; par cancer&#x002C; mais ce principalement dans des &eacute;tudes qui utilisaient une dose quotidienne. Cette hypoth&egrave;se n&rsquo;est pas &eacute;tay&eacute;e par des RCT de grande taille et de longue dur&eacute;e.<\/p>\n<\/li>\n<li>\n<p>80&nbsp;% de la population de l&rsquo;&eacute;tude avait une concentration s&eacute;rique de vitamine&nbsp;D sup&eacute;rieure &agrave; la concentration minimale recommand&eacute;e (&gt;&nbsp;50&nbsp;nmol\/l).&nbsp;Quelques &eacute;tudes observationnelles &agrave; petite &eacute;chelle sugg&egrave;rent que les valeurs initiales pourraient &ecirc;tre plus faibles dans la population belge&#x002C; si bien que toute extrapolation &agrave; la situation belge doit se faire avec prudence<span class='folia-referentie-nummer'><sup>7-11<\/sup><\/span>.<\/p>\n<\/li>\n<\/ul>\n<h2> Conclusion<\/h2>\n<ul>\n<li>\n<p>Cette RCT men&eacute;e &agrave; grande &eacute;chelle sur 5 ans&#x002C; conclut qu&rsquo;un apport mensuel pr&eacute;ventif de vitamine D &agrave; forte dose n&#39;a pas d&#39;effet protecteur sur la mortalit&eacute; globale chez les plus de 60 ans en bonne sant&eacute;. Aucun b&eacute;n&eacute;fice n&rsquo;a par ailleurs &eacute;t&eacute; observ&eacute; en termes de mortalit&eacute; cardiovasculaire ou de mortalit&eacute; par cancer.<\/p>\n<\/li>\n<li>\n<p>La suppl&eacute;mentation en vitamine D est recommand&eacute;e pour pr&eacute;venir les carences en vitamine&nbsp;D chez les groupes &agrave; risque tels que les nourrissons&#x002C; les enfants d&#39;&acirc;ge pr&eacute;scolaire et les femmes enceintes &agrave; peau fonc&eacute;e ou les personnes &acirc;g&eacute;es vivant en institution (<a href='https:\/\/www.cbip.be\/fr\/chapters\/15?frag=13664'>Voir R&eacute;pertoire 14.2.1.2.<\/a>).<\/p>\n<\/li>\n<li>\n<p>Sur la base de ces &eacute;tudes et d&#39;autres &eacute;tudes randomis&eacute;es&#x002C; il n&#39;y a pas d&rsquo;arguments&#x002C; &agrave; ce jour&#x002C; pour recommander une suppl&eacute;mentation en vitamine D en dehors de ces groupes &agrave; risque.<\/p>\n<\/li>\n<\/ul>\n<h2> Sources<\/h2>\n<p><span class='folia-referentie-tekst'><span class='folia-referentie-nummer'>1&nbsp;<\/span>Kristin K D&#x002C; Donald L. T&#x002C; Candace S J. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. <i>Nature reviews Cancer<\/i>. 2007;7(9). doi:10.1038\/nrc2196<br \/> <span class='folia-referentie-nummer'>2&nbsp;<\/span>Neale RE&#x002C; Baxter C&#x002C; Romero BD&#x002C; et al. The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality. <i>The Lancet Diabetes &amp; Endocrinology<\/i>. 2022;10(2):120-128. doi:10.1016\/S2213-8587(21)00345-4<br \/> <span class='folia-referentie-nummer'>3<\/span>&nbsp;Manson JE&#x002C; Cook NR&#x002C; Lee IM&#x002C; et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. <i>New England Journal of Medicine<\/i>. 2019;380(1):33-44. doi:10.1056\/NEJMoa1809944<br \/> <span class='folia-referentie-nummer'>4<\/span>&nbsp;Zhang Y&#x002C; Fang F&#x002C; Tang J&#x002C; et al. Association between vitamin D supplementation and mortality: systematic review and meta-analysis. <i>BMJ<\/i>. 2019;366. doi:10.1136\/bmj.l4673<br \/> <span class='folia-referentie-nummer'>5<\/span>&nbsp;Keum N&#x002C; Lee DH&#x002C; Greenwood DC&#x002C; Manson JE&#x002C; Giovannucci E. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. <i>Annals of oncology\u202f: official journal of the European Society for Medical Oncology<\/i>. 2019;30(5). doi:10.1093\/annonc\/mdz059<br \/> <span class='folia-referentie-nummer'>6<\/span>&nbsp;Mazess RB&#x002C; Bischoff\u2010Ferrari HA&#x002C; Dawson\u2010Hughes B. Vitamin D: Bolus Is Bogus&mdash;A Narrative Review. <i>JBMR Plus<\/i>. 2021;5(12):e10567. doi:10.1002\/jbm4.10567<br \/> <span class='folia-referentie-nummer'>7<\/span>&nbsp;Vaes B&#x002C; Pasquet A&#x002C; Wallemacq P&#x002C; et al. The BELFRAIL (BFC80+) study: a population-based prospective cohort study of the very elderly in Belgium. <i>BMC Geriatr<\/i>. 2010;10:39. doi:10.1186\/1471-2318-10-39<br \/> <span class='folia-referentie-nummer'>8<\/span>&nbsp;Pottelbergh GV&#x002C; Mathe&iuml; C&#x002C; Vaes B&#x002C; Adriaensen W&#x002C; Degryse J. Vitamine D-tekort bij ouderen. :4.<br \/> <span class='folia-referentie-nummer'>9<\/span>&nbsp;Richart T&#x002C; Thijs L&#x002C; Nawrot T&#x002C; et al. The metabolic syndrome and carotid intima-media thickness in relation to the parathyroid hormone to 25-OH-D(3) ratio in a general population. <i>Am J Hypertens<\/i>. 2011;24(1):102-109. doi:10.1038\/ajh.2010.124<br \/> <span class='folia-referentie-nummer'>10<\/span>&nbsp;Moreno-Reyes R&#x002C; Carpentier YA&#x002C; Boelaert M&#x002C; et al. Vitamin D deficiency and hyperparathyroidism in relation to ethnicity: a cross-sectional survey in healthy adults. <i>Eur J Nutr<\/i>. 2009;48(1):31-37. doi:10.1007\/s00394-008-0756-1<br \/> <span class='folia-referentie-nummer'>11&nbsp;<\/span>MacFarlane GD&#x002C; Sackrison JL&#x002C; Body JJ&#x002C; Ersfeld DL&#x002C; Fenske JS&#x002C; Miller AB. Hypovitaminosis D in a normal&#x002C; apparently healthy urban European population. <i>J Steroid Biochem Mol Biol<\/i>. 2004;89-90(1-5):621-622. doi:10.1016\/j.jsbmb.2004.03.042<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Message cl&eacute; L&rsquo;&eacute;tude D-Health est une RCT &agrave; grande &eacute;chelle  [&#8230;]<\/p>\n","protected":false},"author":9,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,40],"tags":[20213,20224],"class_list":["post-175405","post","type-post","status-publish","format-standard","hentry","category-actualites","category-2022-fr","tag-import_tags","tag-import_tags-nl"],"_links":{"self":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/175405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/comments?post=175405"}],"version-history":[{"count":1,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/175405\/revisions"}],"predecessor-version":[{"id":177987,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/posts\/175405\/revisions\/177987"}],"wp:attachment":[{"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/media?parent=175405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/categories?post=175405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/beta.cbip.be\/fr\/wp-json\/wp\/v2\/tags?post=175405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}